Hal Rogers actually said...

"Unfortunately, there is little or no transparency in how the prior authorizations are judged, nor the guidelines by which the reviewers look at the clinical information provided."

"From the dermatology perspective, I can tell you that in many circumstances the cost to the patient is grossly higher."

"One of the things that comes to me that could definitely improve the situation from a transparency standpoint and also from a consistency standpoint would be to have, instead of pharmacy benefit manag..."

"Congressman Hal Rogers, who has been working on this issue for more than a decade."